Skip to main content
SpringerLink
Log in

Vincristine-methotrexate combination chemotherapy and the influence of weight loss on experimental tumour growth

  • Original Articles
  • Vincristine-Methotrexate Combination
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Summary

According to pharmacokinetic reports, vincristine administration should precede methotrexate therapy. Our sequential treatment of L1210 leukaemic mice, in which vincristine was administered before methotrexate therapy, was as effective as treatment with the two drugs given simultaneously. In solid tumour experiments we were unable to show any increase in the antitumour effect of methotrexate when vincristine was injected before methotrexate administration. Consequently, we advocate the re-evaluation of the practice of vincristine →methotrexate therapy as used in many clinical protocols for the treatment of patients with osteosarcoma.

Pretreatment with vincristine resulted in methotrexate-induced weight loss and sometimes in toxic death of the mice. Since the growth of tumours can be modified by regulation of the caloric intake of the host, this aspect was investigated in more detail. The effect of starvation, which was comparable to the effect of drug-induced weight loss, had a retarding effect on tumour growth. The growth rates of smaller tumour volumes were less severely affected than were those of large tumour masses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bender, R. A., Drake, J. C., Fisher, R. I., Chabner, B. A.: Letter to the Editor. N. Engl. J. Med. 292, 432 (1975)

    Google Scholar 

  2. Bender, R. A., Nichols, A. P., Norton, L., Simon, R. M.: Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo. Cancer Treat. Rep. 62, 997 (1978)

    Google Scholar 

  3. Brennan, M. F.: Uncomplicated starvation versus cancer cachexia. Cancer Res. 37, 2359 (1977)

    Google Scholar 

  4. Chello, P. L., Dorick, D. M., Sirotnak, F. M.: Different effects of vincristine on methotrexate uptake by L1210 cells and mouse intestinal epithelia in vitro and in vivo. Proc. Am. Assoc. Cancer Res. 18, 121 (1977)

    Google Scholar 

  5. Chello, P. L., Sirotnak, F. M., Dorick, D. M., Moccio, D. M., Gura, J.: Schedule-dependent synergism of methotrexate and vincristine against L1210 leukemia. Proc. Am. Assoc. Cancer Res. 19, 113 (1978)

    Google Scholar 

  6. EORTC and SIOP: Controlled clinical trial on adjuvant therapy in the treatment of osteosarcoma of the limbs (03 protocol). 1978

  7. Fusner, J. E., Ramu, A., Gratwohl, A.: Effect of vincristine (VCR) on methotrexate (MTX) pharmacokinetics in vivo. Proc. Am. Assoc. Cancer Res. 19, 235 (1978)

    Google Scholar 

  8. Goldman, D., Gupta, V., White, J. C., Loftfield, S.: Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high dose methotrexate-folinic acid “rescue” protocols. Cancer Res. 36, 276 (1976)

    Google Scholar 

  9. Jaffé, N., Frei, E., III, Watts, H., Traggis, D.: High-dose methotrexate in ostogenic sarcoma: a 5-year experience. Cancer Treat. Rep. 62, 259 (1978)

    Google Scholar 

  10. Livingston, R. B., Carter, S. K.: Single agents in cancer chemotherapy. New York: If1/Plenum 1970

    Google Scholar 

  11. Mulder, J. H., Van Putten, L. M.: Lack of vincristine/cyclophosphamide potentiation in different experimental tumour lines. Eur. J. Cancer (in press, 1979)

  12. Mulder, J. H., Smink, T., Van Putten, L. M.: Schedule-dependent effectiveness of CCNU and 5-Fluorouracil in experimental chemotherapy. Eur. J. Cancer 13, 1123 (1977)

    Google Scholar 

  13. Mulder, J. H., Edelstein, M. B., Lelieveld, P., Van Putten, L. M.: Synergism and schedule dependent cytotoxicity of cyclophosphamide and CCNU in experimental cancer chemotherapy. Eur. J. Cancer 14, 537 (1978)

    Google Scholar 

  14. National Cancer Institute: Compilation of clinical protocol summaries. Bethesda: U.S. Department of Health, Education and Welfare 1977

    Google Scholar 

  15. Sandor, R. S.: Brief communication: Effects of fasting on growth and glycolysis on the Ehrlich ascites tumor. J. Natl. Cancer Inst. 56, 427 (1976)

    Google Scholar 

  16. Strogand, J. J., Braunschweiger, P. G., Pollice, A. A., Schiffer, L. M.: Cell kinetic alterations in murine mammary tumours following fasting and refeeding. Eur. J. Cancer 15, 281 (1979)

    Google Scholar 

  17. Warren, R. D., Nichols, A. P., Bender, R. A.: The effect of vincristine on methotrexate uptake and inhibition of DNA synthesis by human lymphoblastoid cells. Cancer Res. 37, 2993 (1977)

    Google Scholar 

  18. Zager, R. F., Frisby, S. A., Oliverio, V. T.: The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. Cancer Res. 33, 1670 (1973)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiobiological Institute TNO, 151, Lange Kleiweg, 2288 GJ, Rijswijk, The Netherlands

    J. H. Mulder & L. M. van Putten

  2. Department of Internal Medicine, Rotterdam Radiotherapeutic Institute, Rotterdam, The Netherlands

    J. H. Mulder

Authors
  1. J. H. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. M. van Putten
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mulder, J.H., van Putten, L.M. Vincristine-methotrexate combination chemotherapy and the influence of weight loss on experimental tumour growth. Cancer Chemother. Pharmacol. 3, 111–116 (1979). https://doi.org/10.1007/BF00254981

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254981

Keywords

Search

Navigation